Takeda Pharmaceutical opens new manufacturing facility in Germany
Invested more than €130 million in the new vaccine plant
Takeda Pharmaceutical Company has announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilised for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than €130 million and will employ up to 200 employees in the vaccine plant.
“This project is one of our most significant investments within our global manufacturing network. We are proud to open this new, state of the art sterile manufacturing plant, which combines a high degree of automation with the most advanced digital and data-driven technologies,” said Thomas Wozniewski, Global Manufacturing and Supply Officer. “Our Singen site has been selected for this investment as our employees have vast experience in lyophilisation technology, which is key for the manufacturing process of Takeda’s dengue vaccine candidate.”
“This new production facility expands Takeda’s global footprint in vaccine manufacturing beyond Hikari, Japan and reinforces our capability to manufacture at scale and meet the global demand that we anticipate for this vaccine,” said Rajeev Venkayya, MD, President of the Global Vaccine Business Unit at Takeda.
Initial construction activities started at the end of 2016 and the plant is now ready to begin production for packaging, with the goal to launch end-to-end production closer to licensure.